“The #1 Tech Opportunity of the Decade”

On February 8th, Luke Lango is making his biggest call of 2023. He’s recommending technology (that you’ve likely never heard of) that could help 122 million people… And mint up to $3 trillion in wealth.

Wed, February 8 at 8:00PM ET

EW Is a Stock for the Long Term — the REALLY Long Term

One area companies are chasing right now is helping us live longer. Google Ventures President Bill Maris said a few months ago that humans may one day be able to live to age 500.

edwards-lifesciences-ew-stock-logo-185Well, if that’s going to happen, eating kale isn’t going to be enough to get us there. We’re going to need a little bit — or more likely a lot — of tweaking along the way.

That’s where these life sciences companies come in, and there are some interesting opportunities for us as investors.

Edwards Lifesciences Corp (NYSE:EW) is one I really like right now. It leads the world in the science of heart valves and hemodynamic monitoring — also known as vascular surgery. The company is working on new technologies and products that treat structural heart disease. Edwards’ goal is to help people live longer, healthier and more productive lives.

Who can argue with that?

I love the heart-valve companies and have followed them for a very long period of time. In fact, I bought into EW last year and it was a juggernaut, making a lot of money in a short time. While it’s pulled back a bit recently — it’s trading about 15% from its 52-week high — I really like it here.

Drilling down into the numbers, you’ll notice that this company’s execution has been phenomenal. The company has beaten the Street in each of the last four quarters. In the most recent first quarter, sales increased 13%, gross margins increased from 72% to 77% and operating margins grew from less than 15% to 27.5%.

Those are impressive results, and EW pulled it off even with a higher tax rate.

Management also provided pretty good guidance for the future, so I’m very comfortable with where the stock is trading right now — as well as how it’s situated for the near term — from a risk/reward standpoint.

Having said that, I want to make it clear that EW is not cheap according to traditional valuation metrics. It trades at a forward price-to-earnings ratio of 28 and a price/earnings-to-growth ratio of more than 2.

And as you may know, the biotech sector has been quite volatile lately, so keep risk in mind as you think about this stock.

I’m looking for Edwards to continue gaining market and producing innovative treatments for heart disease, moving the stock higher over time. If we’re all going to live a lot longer, we’re going to need some extra cash along the way.

Curious what Wall Street insider Charles Payne really thinks? Get more behind-the-scenes insights, valuable market research and hands-on guidance including live stock recommendations from Fox Business’s rising star. Charles Payne’s Smart Talk is absolutely FREE for a limited-time only. Sign up today!

More From InvestorPlace

Article printed from InvestorPlace Media, https://investorplace.com/2015/05/ew-stock-edwards-lifesciences-long-term/.

©2023 InvestorPlace Media, LLC